Local

Pfizer asks US to allow 4th COVID vaccine dose for seniors

Pfizer and a BioNTech partner asked U.S. regulators on Tuesday to approve an additional booster dose of their COVID-19 vaccine for the elderly, saying data from Israel suggests that the elderly will benefit. Currently, the US is urging two key shots followed months later by a booster dose for everyone aged 12 and over. The new app seeks to add a fourth download only to the population over the age of 65 most affected by the pandemic. The Food and Drug Administration and the Centers for Disease Control will have to approve the request. If so, a key question would be how soon the elderly would be advised to roll up their sleeves. While authorities say vaccines continue to offer strong protection against serious diseases, they have not been as good at treating milder infections, especially those caused by a small mutant. With COVID-19 cases finally plummeting after the intense micron wave, public health experts are beginning to look ahead to the next steps they may need – if a new variant appears or, to rule it out, if they try to strengthen protecting the coronavirus in the fall At the same time, people are getting vaccines against the flu. Speaking on CBS’s “Face the Nation” on Sunday, Pfizer CEO Albert Bourla signaled the company’s plans. “The protection you receive from the third party is quite good, really very good for hospitalization and death. “It’s not very good against infections,” he said. milder infections, about six months after the last dose, and calls for a third vaccine increased when it became clear that the vaccine was not as potent against the mutated micron as it was against previous versions of the virus. Vaccination is the prevention of serious illnesses, not mild infections, and CDC preliminary data show that shots still do a good job of it.During the omicron wave, the efficacy against hospitalization was 91% in people who had received a booster. two months earlier and 78% by the fourth month after this reminder, Pfizer Israel, which has already offered a second souvenir to people aged 60 and over and to healthcare workers. While some early data left it unclear how much benefit another vaccine offered — or for how long — Pfizer said Tuesday that an analysis of the health records of more than 1.1 million Israeli seniors showed confirmed infections were twice as low and the rates of four seriously ill times lower among those who received two souvenirs instead of just one. Pfizer also reported an ongoing study by health care workers that followed a jump in antibodies to fight the virus after taking the additive booster. In the US So far, a fourth dose is only recommended for people with severely weakened immune systems. three doses are needed for the best possible protection.

Pfizer and a BioNTech partner asked U.S. regulators on Tuesday to approve an additional booster dose of their COVID-19 vaccine for the elderly, saying data from Israel suggests that the elderly will benefit.

Currently, the US is urging two main shots followed months later by a booster dose for everyone aged 12 and over. The new app seeks to add a fourth download only to the population over the age of 65 most affected by the pandemic.

The Food and Drug Administration and the Centers for Disease Control will have to approve the request. If so, a key question would be how soon the elderly would be advised to roll up their sleeves.

While authorities say vaccines continue to offer strong protection against serious diseases, they do not tolerate milder infections as well, especially those caused by the mutated micron. With COVID-19 cases finally plummeting after the intense micron wave, public health experts are beginning to look ahead to the next steps they may need – if a new variant appears or, to rule it out, if they try to strengthen protect the coronavirus in the fall at the same time people are getting flu shots.

Speaking on CBS’s “Face the Nation” on Sunday, Pfizer CEO Albert Bourla outlined the company’s plans.

“The protection you get from the third party is quite good, in fact good enough for hospitalization and death. “It’s not so good against infections,” he said. “But we’re just submitting that data to the FDA and then we’ll see what non-Pfizer experts have to say.”

The US Memorial Campaign was based on evidence that the effectiveness of the vaccines, especially against milder infections, was declining about six months after the last dose. Calls for a third vaccine were raised when it became clear that the vaccines were not as potent against the mutant micron as they were against previous versions of the virus.

Many scientists say that the ultimate goal of vaccination is to prevent serious illnesses rather than mild infections, and early CDC data show that vaccines still do a good job. During the micron wave, the efficacy against hospitalization was 91% in individuals who had received their booster two months earlier and 78% in the fourth month after that booster.

Pfizer has backed up its new data application from Israel, which has already offered a second boost to people aged 60 and over and healthcare workers.

While some early data left it unclear how much benefit another vaccine offered – or for how long – Pfizer said Tuesday that an analysis of the health records of more than 1.1 million Israeli seniors showed that the confirmed infections were twice as low and the rates as severe. diseases four times lower than those receiving two enhancers instead of just one.

Pfizer also reported an ongoing study by healthcare workers that followed a jump in antibodies to the virus after receiving the add-on booster.

In the US so far, a fourth dose is only recommended for people with severely weakened immune systems, who need three doses for the best possible protection.

Pfizer asks US to allow 4th COVID vaccine dose for seniors Source link Pfizer asks US to allow 4th COVID vaccine dose for seniors

Related Articles

Back to top button